

PROVIDER N. 157

GISEA/OEG INTERNATIONAL SYMPOSIUM 2026

Rheumatology and complex diseases: next steps to the future

20-22 Maggio 2026

Sala Convegni Palazzo San Giorgio - Trani

PROGRAMMA SCIENTIFICO

Board Scientifico

- Roberto Caporali
- Fabrizio Conti
- Florenzo Iannone
- Fabiola Atzeni
- Elisa Gremese
- Marco Sebastiani
- Ennio Giulio Favalli

Razionale

This congress is devised to address the evolving landscape of rheumatology by focusing on several key strategic themes:

Complexity and Precision Medicine

The meeting emphasizes moving beyond traditional classification toward understanding disease complexity and heterogeneity. Multiple sessions focus on disease interception and prevention (PsA screening in psoriasis patients), subgroup identification in systemic sclerosis, mechanism-driven approaches in vasculitis, precision care in SLE and vasculitis

Personalized Treatment Strategies. Rather than one-size-fits-all approaches, the program explores how different factors should drive therapeutic decisions, such as synovitis-driven therapy in rheumatoid arthritis, serology-driven therapy considerations, comorbidity-driven therapy adaptations

Emerging Therapeutic Frontiers. The congress explores novel targeted therapies (particularly for Sjögren's and systemic sclerosis), artificial intelligence applications in myositis, new drugs for obesity management in rheumatic diseases

Critical Comorbidities. Dedicated attention to factors that complicate management, namely obesity and its impact on treatment, interstitial lung disease in RA, infections and prophylaxis in immunocompromised patients, post-COVID considerations

Pathogenetic Understanding. Emphasis on mechanisms linking related conditions (skin psoriasis to PsA) and evolving therapeutic targets (B cells in SLE).

Targeted Therapies Reshaping Clinical Practice

- ◇ Sjögren's Syndrome "Rethinking nomenclature in the era of targeted therapies" acknowledges that new treatments (likely anti-CD40, ianalumab, others) are changing how we conceptualize and classify the disease. Understanding which patients benefit from which targeted approaches
- ◇ Systemic Sclerosis. "Novel therapeutics and subgroup insights" reflects the emergence of multiple new treatment options (anti-fibrotics, immunomodulators, vascular therapies). Recognition that SSc is not one disease but multiple phenotypes requiring different interventions. Integration of organ-specific and systemic approaches
- ◇ Myositis. "On the brink of a revolution" with JAK inhibitors and other targeted therapies. Artificial Intelligence integration: Representing the cutting edge where machine learning aids in diagnosis, classification, treatment prediction, and outcome assessment. Moving from broad immunosuppression to targeted pathway inhibition
- ◇ SLE. "B cells reloaded" suggests evolution beyond rituximab toward next-generation B-cell targeting (anifrolumab, obinutuzumab, telitacicept, others). Pursuit of "cure" rather than simply disease control. Understanding B-cell heterogeneity and different depletion/modulation strategies

Overall Vision: This congress represents rheumatology at an inflection point. The field is moving from a relatively simple paradigm (diagnose disease, suppress inflammation) to a sophisticated, multi-dimensional approach. The "next steps to the future" are not incremental improvements but fundamental transformations in how rheumatologists conceptualize disease, select treatments, and care for patients. This congress serves as both a roadmap and a call to action for the rheumatologic community to embrace this complexity and build the skills, knowledge, and collaborative networks necessary to deliver truly personalized, precision medicine to patients with rheumatic diseases.

Obiettivo Formativo: DOCUMENTAZIONE CLINICA. PERCORSI CLINICO-ASSISTENZIALI DIAGNOSTICI E RIABILITATIVI, PROFILI DI ASSISTENZA - PROFILI DI CURA (3)

Destinatari dell'iniziativa: 130 Medici Chirurghi specialisti in Medicina Interna, Reumatologia, Allergologia ed Immunologia Clinica, Malattie Apparato Respiratorio, Ortopedia e traumatologia

Mercoledì' 20 maggio 2026

Welcome light lunch

Programma ECM

14.30 – 15.00 Apertura lavori: Giovanni Lapadula, Gianfranco Ferraccioli
Saluti istituzionali

Chairman:

15.00 – 15.30 Lettura Magistrale: From the Covid era to the post-Covid era !
Pierluigi Lopalco

SESSION I

Title: Spondyloarthritis

Chairman: Ennio Giulio Favalli (Milano)

15.30 – 15.50 **From skin psoriasis to PsA: what pathogenetic mechanisms?**

Francesco Ciccia (Napoli)

15.50 – 16.10 **PsA interception in patient with psoriasis: true prevention or very early treatment of a subclinical disease?**

Luca Idolazzi (Verona)

16.10 – 16.30 **From difficult-to-treat to difficult-to-manage PsA: definition and treatment of a complex entity**

Maria Sole Chimenti (Roma)

16.30 – 17.00 Discussion

17.00 – 17.30 Sponsor Lecture No ECM – Johnson&Johnson

17.30 – 18.00 Sponsor Lecture No ECM – Eli Lilly

18.00 – 19.00 Assemblea dei Centri GISEA Gruppo Italiano Studio Early Arthritis

Programma ECM

Giovedì 21 maggio 2026

SESSION II

Title: Rheumatoid Arthritis

Chairman: Fabrizio Conti (Roma)

09.00 – 09.20 **When synovitis drives therapy**

Elisa Gremese (Milano)

09.20 – 09.40 **When serology drives therapy**

Serena Bugatti (Pavia)

09.40 – 10.00 **When comorbidities drive therapy**

Florenzo Iannone (Bari)

10.00 – 10.30 Discussion

10.30 – 11.00 Coffee break

SESSION III

Title: Connective tissue disease (Miositi, Sjogren, SSc)

Chairman: Fabiola Atzeni (Messina)

11.00 – 11.20 **Sjogren's unveiled: rethinking nomenclature in the era of targeted therapies**

Michele Bombardieri (London)

11.20 – 11.40 **Targeting Complexity: Novel Therapeutics and Subgroup Insights in Systemic Sclerosis**

Marco Matucci-Cerinic (Milano)

11.40 – 12.00 **Myositis on the Brink of a Revolution: New Therapies and the Power of Artificial Intelligence**

Latika Gupta (Manchester)

12.00 – 12.30 Discussion

12.30 – 13.30 Lunch

Programma ECM

SESSION IV

Title: Comorbidities: obesity, ILD, infections and e profilaxis

Chairman: Marco Sebastiani (Parma)

13.30- 13.50 How the obesity changes the management of rheumatic diseases, old drugs and new opportunity of treatment

Roberto Caporali (Milano)

13.50 – 14.10 The management of rheumatoid arthritis related interstitial lung disease in light of new international recommendations

Philippe Dieude (Parigi)

14.10 – 14.30 New drugs and old infections. Prophylaxis and vaccination in immunocompromised patients

Delia Goletti (Roma)

14.30 – 15.00 Discussion

15.00 – 15.30 Sponsor Lecture No ECM - Abbvie

15.30 – 16.00 Sponsor Lecture No ECM – Eli Lilly

16.00 – 16.30 Sponsor Lecture No ECM – Boehringer Ingelheim

16.30 – 17.00 Sponsor Lecture No ECM – UCB Pharma

17.00 – 17.30 Coffee break

Venerdì 22 maggio 2026

Programma ECM

SESSIONE V

Title: Immune complexity in motion: SLE and Vasculitis towards precision care

Chairman: Elisa Gremese (Milano)

09.00 – 09.20 **B cells reloaded: evolution of a therapeutic target towards a cure for SLE**

Gianfranco Ferraccioli

09.20 – 09.40 **Difficult-to-treat SLE: recognition, prevention, and treatment approaches**

Matteo Piga (Cagliari)

09.40 – 10.00 **Redefining vasculitis from ANCA associated and EGPA to GCA: moving toward targeted, mechanism-driven approaches**

Roberto Padoan (Padova)

10.00 – 10.30 Discussion

10.30 – 11.00 Coffee break

11.00 – 11.30 Sponsor Lecture No ECM - Novartis

11.30 – 12.00 Sponsor Lecture No ECM - Alfasigma

12.00 – 12.30 Sponsor Lecture No ECM

12.30 – 14.00 Lunch

14.00– 17.00 **Sessione GISEA REGISTRY NO ECM**
Safety and drug retention of bDMARDs and tsDMARDs

Chairmen: Roberto Caporali (Milano), Florenzo Iannone (Bari)

14.00 – 15.00 **GISEA: one year in Review**

15.00– 16.10 **GISEA Registry: What's cooking in the pot? (comunicazioni di 5 min + 5 discussione)**

16.10 – 17.00 **GISEA registry: where are we now? (4 comunicazioni giovani)**

Conclusions & next steps